Celgene Corporation and AstraZeneca have initiated a clinical development program of AstraZeneca’s durvalumab, an investigational human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) in hematologic disorders.

The program is part of a strategic collaboration with AstraZeneca and its global biologics research and development arm MedImmune, to develop and commercialize durvalumab across a range of blood cancers, including non-Hodgkin’s lymphoma, myelodysplastic syndromes, and multiple myeloma. The program will initially include four studies.

Source: Celgene (AstraZeneca)